These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36303829)

  • 1. Development and validation of a m
    Chen Y; Xia L; Peng Y; Wang G; Bi L; Xiao X; Li C; Li W
    Front Oncol; 2022; 12():947808. PubMed ID: 36303829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 4. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
    Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
    Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Genomic Instability of m
    Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
    Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
    [No Abstract]   [Full Text] [Related]  

  • 7. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analyses of molecular features, prognostic values, and regulatory functionalities of m
    Ping Y; Huang J; Zhu J; Sun Z; Shang A; Chen C; Liu W; Li D
    Clin Epigenetics; 2023 Apr; 15(1):60. PubMed ID: 37029420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Xu F; Huang X; Li Y; Chen Y; Lin L
    Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
    Tian L; Wang Y; Tian J; Song W; Li L; Che G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An N
    Chu X; Wang W; Sun Z; Bao F; Feng L
    Math Biosci Eng; 2022 Jan; 19(1):253-270. PubMed ID: 34902990
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
    Wang X; Zhao C; Huang D; Liu Z; Liu M; Lin F; Lu Y; Jia J; Lin L; Lin X; Li H; Chen Z
    Front Immunol; 2022; 13():923533. PubMed ID: 35860262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a Novel Prognostic Model in Lung Adenocarcinoma Based on 7-Methylguanosine-Related Gene Signatures.
    Lu F; Gao J; Hou Y; Cao K; Xia Y; Chen Z; Yu H; Chang L; Li W
    Front Oncol; 2022; 12():876360. PubMed ID: 35785179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the Signature Associated With m
    Guo B; Zhang H; Wang J; Wu R; Zhang J; Zhang Q; Xu L; Shen M; Zhang Z; Gu F; Zeng W; Jia X; Yin C
    Front Genet; 2021; 12():656114. PubMed ID: 34178026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
    Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
    Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function and prognostic value of N6-methyladenosine-modified RNAs in lung adenocarcinoma.
    Liu J; Zheng Z; Zhong J
    J Gene Med; 2023 Jan; 25(1):e3454. PubMed ID: 36282144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.
    Sun J; Ping Y; Huang J; Zeng B; Ji P; Li D
    Front Cell Dev Biol; 2021; 9():705962. PubMed ID: 34422827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
    Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
    Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.